NASDAQ:KALVKalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KALV shares have increased by 46.4% and is now trading at $12.97. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, September 14th 2020. View our earnings forecast for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) announced its quarterly earnings data on Wednesday, July, 1st. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.28. The specialty pharmaceutical company earned $3.82 million during the quarter, compared to analyst estimates of $2.05 million. Kalvista Pharmaceuticals had a negative return on equity of 31.21% and a negative net margin of 229.45%. View Kalvista Pharmaceuticals' earnings history.

4 brokers have issued 12 month price targets for Kalvista Pharmaceuticals' stock. Their forecasts range from $25.00 to $31.00. On average, they anticipate Kalvista Pharmaceuticals' share price to reach $29.00 in the next year. This suggests a possible upside of 123.6% from the stock's current price. View analysts' price targets for Kalvista Pharmaceuticals.

Headlines about KALV stock have been trending negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next few days. View the latest news about Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a decline in short interest in June. As of June 30th, there was short interest totaling 315,500 shares, a decline of 7.5% from the June 15th total of 341,200 shares. Based on an average trading volume of 139,800 shares, the days-to-cover ratio is currently 2.3 days. Currently, 2.5% of the company's stock are sold short. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include Phathom Pharmaceuticals (PHAT), Retrophin (RTRX), Gossamer Bio (GOSS), Passage Bio (ORIC), ImmunoGen (IMGN), Humanigen (HGEN), Omeros (OMER), Cara Therapeutics (CARA), G1 Therapeutics (GTHX), Endo International (ENDP), Dynavax Technologies (DVAX), Morphic (MORF), Aprea Therapeutics (APRE), Stoke Therapeutics (STOK) and Assembly Biosciences (ASMB). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Agile Therapeutics (AGRX), GALAPAGOS NV/S (GLPG), Ritter Pharmaceuticals (RTTR), SCYNEXIS (SCYX) and Anavex Life Sciences (AVXL).

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $12.97.

Kalvista Pharmaceuticals has a market capitalization of $231.51 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.

The official website for Kalvista Pharmaceuticals is www.kalvista.com.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]